- Home
- HUYA vs CTNM Comparison
HUYA vs CTNM Comparison
Compare HUYA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUYA | CTNM |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 489.4M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HUYA | CTNM |
|---|---|---|
| Price | $2.41 | $14.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 724.3K | 512.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 81.37% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.08 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $3.86 |
| 52 Week High | $4.93 | $16.91 |
Technical Indicators
Market Signals| Indicator | HUYA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 53.64 |
| Support Level | $2.15 | $11.73 |
| Resistance Level | $2.54 | $15.60 |
| Average True Range (ATR) | 0.08 | 1.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 70.39 | 42.62 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.